{"id":"W2791666791","doi":"10.1200/jco.2018.36.4_suppl.204","title":"Phase II LAPACT trial of <i>nab</i>-paclitaxel (<i>nab</i>-P) plus gemcitabine (G) for patients with locally advanced pancreatic cancer (LAPC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Neutropenia; Gemcitabine; Clinical endpoint; Internal medicine; Regimen; Phases of clinical research; Adverse effect; Febrile neutropenia; Induction chemotherapy; Pancreatic cancer; Nab-paclitaxel; Anemia; Gastroenterology; Progressive disease; Oncology; Surgery; Cancer; Clinical trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001283108,0.001387942,0.001117809,0.0003653606,0.0003322737,0.0009190172,0.0009337576,0.0009058996,0.005521056],"category_scores_gemma":[0.0009640014,0.0004843765,0.0008861649,0.0003333808,0.0007765871,0.0007917299,0.0004854502,0.003750525,0.0008323943],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009869952,"about_ca_system_score_gemma":0.001459531,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001343444,"about_ca_topic_score_gemma":0.003191797,"domain_scores_codex":[0.9997005,0.0001811674,0.00001049456,0.00003728254,0.00002496885,0.00004548625],"domain_scores_gemma":[0.9994156,0.00008873756,0.0001531051,0.00004371143,0.00003258034,0.0002663474],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8431386,0.03688442,0.00425131,0.001133207,0.0007355257,0.0002973837,0.0002119355,0.002879812,0.02255231,0.0005850278,0.01152988,0.07580058],"study_design_scores_gemma":[0.7993233,0.1903936,0.003895018,0.00004910952,0.000202654,0.0002129456,0.00003413637,0.001040782,0.001595599,0.0001804161,0.003056426,0.00001611446],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9694139,0.004827548,0.001231531,0.001556098,0.0004233002,0.01028777,0.003713224,0.0003230082,0.008223593],"genre_scores_gemma":[0.9692563,0.002833596,0.002715852,0.001952725,0.0003661477,0.009806383,0.006069874,0.00005564335,0.00694337],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005521056,"threshold_uncertainty_score":0.01846981,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1013342412014455,"score_gpt":0.5064914284515502,"score_spread":0.4051571872501046,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}